Product Description
Novartis is developing EYU688 for Dengue Fever. It is a NS4B inhibitor in Phase 2. (Sourced from: https://www.novartis.com/research-development/novartis-pipeline?search_api_fulltext=EYU-688)
Mechanisms of Action: NS4B Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: Europe
Company Founding Year: 1996
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Brazil, India, Malaysia, Singapore, Vietnam
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Dengue
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06006559 |
CEYU688A12201 | P2 |
Recruiting |
Dengue |
2026-09-07 |
12% |
2025-07-31 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|